Related Experiment Video
Updated: Jun 15, 2026
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Contact activation and factor VII after the use of an activated prothrombin complex concentrate (FEIBA) in
G Mariani1, B N Bouma, M G Mazzucconi
1Institute of Hematology, University of Rome, Italy.
Administration of a brand of activated prothrombin complex concentrate (FEIBA) to hemophiliacs with high-titre inhibitor to factor VIII, induced a shortening of the prothrombin time and thrombotest clotting time. This effect stems partly from the presence in the concentrate of high amounts of activated factor VII (alpha-VII a) which indeed after the infusion, were detected in the plasma of Hemophiliacs. The attained levels of factor alpha-VII a were shown to be proportional to the dose of concentrate administered. This form of activated factor VII was not generated as a result of activation of the contact activation mechanism, since after the infusion of the concentrate no changes were detected in the components of this system. The infused factor VII was indeed present in an activated form and this was further substantiated by the infusion of the concentrate in factor VII deficient patients. These observations suggest that factor alpha-VII a is not generated in vivo and thus is of exogenous origin. The clinical effect may well be due to the presence of this form of activated factor VII; in this context the alternative pathway involving factors IX and X should be implicated.
Administration of a brand of activated prothrombin complex concentrate (FEIBA) to hemophiliacs with high-titre inhibitor to factor VIII, induced a shortening of the prothrombin time and thrombotest clotting time. This effect stems partly from the presence in the concentrate of high amounts of activated factor VII (alpha-VII a) which indeed after the infusion, were detected in the plasma of Hemophiliacs. The attained levels of factor alpha-VII a were shown to be proportional to the dose of concentrate administered. This form of activated factor VII was not generated as a result of activation of the contact activation mechanism, since after the infusion of the concentrate no changes were detected in the components of this system. The infused factor VII was indeed present in an activated form and this was further substantiated by the infusion of the concentrate in factor VII deficient patients. These observations suggest that factor alpha-VII a is not generated in vivo and thus is of exogenous origin. The clinical effect may well be due to the presence of this form of activated factor VII; in this context the alternative pathway involving factors IX and X should be implicated.
Related Concept Videos
01:20Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:29Venous Thrombosis III: Interprofessional Care
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:09Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
01:16Clot Retraction and Fibrinolysis